Astragaloside IV for Heart Failure: Preclinical Evidence and Possible Mechanisms, A Systematic Review and Meta-Analysis.
10.1007/s11655-023-3636-x
- Author:
Xing-Xing LI
1
;
Dong LI
1
;
Xiao-Yun CUI
1
;
Kun ZHOU
1
;
Jing LIU
1
;
Jin-Jin LU
1
;
Yang WU
1
;
Qian LIN
2
;
Yan LI
3
Author Information
1. Department of Cardiology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, 100078, China.
2. Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, China.
3. Department of Cardiology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, 100078, China. erzitaba@163.com.
- Publication Type:Journal Article
- Keywords:
astragaloside IV;
heart failure;
pre-clinical evidence;
systematic review
- MeSH:
Animals;
Mice;
Rats;
Stroke Volume;
Ventricular Function, Left;
Heart Failure/drug therapy*;
Natriuretic Peptide, Brain
- From:
Chinese journal of integrative medicine
2023;29(7):626-633
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To explore the cardioprotective effects of astragaloside IV (AS-IV) in heart failure (HF).
METHODS:PubMed, Excerpta Medica Database (EMBASE), Cochrane Library, Web of Science, Wanfang Database, Chinese Bio-medical Literature and Retrieval System (SinoMed), China Science and Technology Journal Database (VIP), and China National Knowledge Infrastructure (CNKI) were searched from inception to November 1, 2021 for animal experiments to explore AS-IV in treating HF in rats or mice. The left ventricular ejection fraction (LVEF), left ventricular fractional shortening (LVFS), left ventricular end-diastolic dimension (LVEDD), left ventricular end-systolic dimension (LVESD), left ventricular weight-to-body weight (LVW/BW) and B-type brain natriuretic peptide (BNP) were recorded. The qualities of included studies were assessed by the risk of bias according to the Cochrane handbook. Meta-analysis was performed using Stata 13.0.
RESULTS:Twenty-one articles involving 558 animals were considered. Compared with the control group, AS-IV improved cardiac function, specifically by increasing LVEF (mean difference (MD)=6.97, 95% confidence interval (CI)=5.92 to 8.03, P<0.05; fixed effects model) and LVFS (MD=7.01, 95% CI=5.84 to 8.81, P<0.05; fixed effects model), and decreasing LVEDD (MD=-4.24, 95% CI=-4.74 to -3.76, P<0.05; random effects model) and LVESD (MD=-4.18, 95% CI=-5.26 to -3.10, P<0.05; fixed effects model). In addition, the BNP and LVW/BW levels were decreased in the AS-IV treatment group (MD=-9.18, 95% CI=-14.13 to -4.22, P<0.05; random effects model; MD=-1.91, 95% CI=-2.42 to -1.39, P<0.05; random effects model).
CONCLUSIONS:AS-IV is a promising therapeutic agent for HF. However, this conclusion needs to be clinically validated in the future.
